Updated aluminum pharmacokinetics following infant exposures through diet and vaccination

Vaccine

Volumn 29, Issue 51, 2011, Pages 9538-9543

  Mitkus, Robert J ^a   King, David B ^a   Hess, Maureen A ^a   Forshee, Richard A ^a   Walderhaug, Mark O ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Adjuvant; Aluminum; Modeling; Pharmacokinetics; Safety

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ANTACID AGENT; TOXIC SUBSTANCE;

ARTICLE; BODY WEIGHT; CHILD; DISEASE REGISTRY; FOOD INTAKE; GLOMERULUS FILTRATION RATE; HUMAN; INFANT; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM; HUMANS; VACCINATION;

EID: 81955167447     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.124     Document Type: Article

References (31)

1. Keith L.S., Jones D.E., Chou C.H. Aluminum toxicokinetics regarding infant diet and vaccinations. Vaccine 2002, 20(Suppl. 3):S13-S17.
2. ACIP (Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention) Policy statement - recommended childhood and adolescent immunization schedules - United States, 2011. Pediatrics 2011, 127(2):387-388.
3. NHANES (National Health and Nutrition Examination Survey). Available from: 2008 [accessed 01.03.11]. http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/BMX_E.htm.
4. ATSDR (Agency for Toxic Substances and Disease Registry). Toxicological profile for aluminum. Atlanta, GA; 2008.
5. Priest N.D. The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update. J Environ Monit 2004, 6(5):375-403.
6. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453(7198):1122-1126.
7. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004, 82(5):497-505.
8. Yokel R.A., McNamara P.J. Aluminium toxicokinetics: an updated minireview. Pharmacol Toxicol 2001, 88(4):159-167.
9. Sedman A.B., Klein G.L., Merritt R.J., Miller N.L., Weber K.O., Gill W.L., et al. Evidence of aluminum loading in infants receiving intravenous therapy. N Engl J Med 1985, 312(21):1337-1343.
10. Miu A.C., Andreescu C.E., Vasiu R., Olteanu A.I. A behavioral and histological study of the effects of long-term exposure of adult rats to aluminum. Int J Neurosci 2003, 113(9):1197-1211.
11. Lu Z.Y., Gong H., Amemiya T. Aluminum chloride induces retinal changes in the rat. Toxicol Sci 2002, 66(2):253-260.
12. Krewski D., Yokel R.A., Nieboer E., Borchelt D., Cohen J., Harry J., et al. Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. J Toxicol Environ Health B: Crit Rev 2007, 10(Suppl. 1):1-269.
13. Eickhoff T.C., Myers M. Workshop summary aluminum in vaccines. Vaccine 2002, 20(Suppl. 3):S1-S4.
14. Lach B., Cupler E.J. Macrophagic myofasciitis in children is a localized reaction to vaccination. J Child Neurol 2008, 23(6):614-619.
15. Kalil R.K., Monteiro A., Lima M.I., Silveira E.B., Foltran F.S., Martins C.E., et al. Macrophagic myofasciitis in childhood: the role of scanning electron microscopy/energy-dispersive spectroscopy for diagnosis. Ultrastruct Pathol 2007, 31(1):45-50.
16. Cranmer J.M., Wilkins J.D., Cannon D.J., Smith L. Fetal-placental-maternal uptake of aluminum in mice following gestational exposure: effect of dose and route of administration. Neurotoxicology 1986, 7(2):601-608.
17. Moreno A., Domínguez C., Ballabriga A. Aluminum in the neonate related to parenteral nutrition. Acta Paediatr 1994, 83(1):25-29.
18. ICRP (International Commission on Radiological Protection) Report on the Task Group on reference man 1975, ICRP Publication 23.
19. Use of World Health Organization and CDC Growth Charts for children aged 0-59 months in the United States. Mortal Morb Wkly Rep 2010, 59(RR-9).
20. Yokel R.A. Toxicity of gestational aluminum exposure to the maternal rabbit and offspring. Toxicol Appl Pharmacol 1985, 79(1):121-133.
21. Priest N.D., Newton D., Day J.P., Talbot R.J., Warner A.J. Human metabolism of aluminium-26 and gallium-67 injected as citrates. Hum Exp Toxicol 1995, 14(3):287-293.
22. Gibaldi M., Perrier D. Pharmacokinetics 1982, Marcel Dekker, New York.
23. Allegaert K., Verbesselt R., Naulaers G., van den Anker J.N., Rayyan M., Debeer A., et al. Developmental pharmacology: neonates are not just small adults. Acta Clin Belg 2008, 63(1):16-24.
24. Tetelbaum M., Finkelstein Y., Nava-Ocampo A.A., Koren G. Back to basics: understanding drugs in children: pharmacokinetic maturation. Pediatr Rev 2005, 26(9):321-328.
25. Schwartz G.J., Feld L.G., Langford D.J. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984, 104(6):849-854.
26. Greger J.L., Baier M.J. Excretion and retention of low or moderate levels of aluminium by human subjects. Food Chem Toxicol 1983, 21(4):473-477.
27. Flarend R.E., Hem S.L., White J.L., Elmore D., Suckow M.A., Rudy A.C., et al. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine 1997, 15(12-13):1314-1318.
28. Borak J., Wise J.P. Does aluminum exposure of pregnant animals lead to accumulation in mothers or their offspring?. Teratology 1998, 57(3):127-139.
29. ATSDR (Agency for Toxic Substances and Disease Registry). Toxicological profile for aluminum. Atlanta, GA; 1999.
30. Schroder K., Tschopp J. The Inflammasomes. Cell 2010, 140(6):821-832.
31. R Foundation for Statistical Computing. 2011. Available from: http://www.r-project.org/.